In light of the biomedical significance of metallo-β-lactamases (MβLs), ten new mercaptoacetic acid thioester amino acid derivatives were synthesized and characterized. Biological activity assays indicated that all these synthesized compounds are very potent inhibitors of L1, exhibiting an IC 50 value range of 0.018−2.9 μM and a K i value range of 0.11−0.95 μM using cefazolin as substrate. Partial thioesters also showed effective inhibitory activities against NDM-1 and ImiS with an IC 50 value range of 12−96 and 3.6−65 μM, respectively. Also, all these thioesters increased susceptibility of E. coli cells expressing L1 to cefazolin, indicated by a 2−4-fold reduction in MIC of the antibiotic. Docking studies revealed potential binding modes of the two most potent L1 inhibitors to the active site in which the carboxylate group interacts with both Zn(II) ions and Ser221. This work introduces a highly promising scaffold for the development of metallo-β-lactamase L1 inhibitors. KEYWORDS: Antibiotic resistance, metallo-β-lactamase, subclass B3, L1, inhibitor, mercaptoacetic acid thioester β-Lactam antibiotics, which include penicillins, cephalosporins, and carbapenems, remain the most important and frequently used antimicrobial agents, constituting more than 50% of the antibiotics prescribed worldwide.1 However, the overuse of antibiotics in the clinical setting as well as animal production has resulted in resistance 2 conferred, among other resistance mechanisms, by the production of β-lactamases. More than a thousand β-lactamases have been isolated, and these enzymes have been categorized into classes A to D, depending on their amino acid sequence homologies.1 Enzymes from classes A, C, and D comprise the serine β-lactamases. They use a catalytic mechanism that is characterized by the nucleophilic attack of an active-site serine on the β-lactam carbonyl, ultimately causing cleavage of the β-lactam ring. Class B enzymes, or metallo-β-lactamases (MβLs), require either one or two Zn(II) ions per enzyme molecule for full catalytic activity, and these enzymes inactivate all clinically important β-lactams except aztreonam. According to amino acid sequence homologies MβLs are divided into subclasses B1−B3, based on amino acid sequence homologies.3 MβLs from subclasses B1 and B3 can inactivate nearly all β-lactam antibiotics. Contrarily, B2 enzymes possess a narrow substrate preference for carbapenems. There are no known clinical inhibitors of the MβLs to date.